JAK2 and myeloproliferative neoplasm: These results revealed that the positive rate of JAK2 V617F mutation in MPN (62.5%) is significantly different from that in non-MPN (8.0%); therefore, the incidence of the JAK2 V617F mutation may be a reliable diagnostic criterion in MPN.